-
公开(公告)号：US11560425B2
公开(公告)日：2023-01-24
申请号：US16626625
申请日：2018-06-27
Applicant: Neuracle Science Co., Ltd.
Inventor： Bongcheol Kim , Eun Bee Cho , Dong Sik Kim , Jae-Keun Lee , Soon-gu Kwon , Jae Young Seong , Juwon Shim , Tae Woo Kim , Shin-hyuk Kang
Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
公开(公告)号：US11332521B2
公开(公告)日：2022-05-17
申请号：US16348058
申请日：2017-11-07
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Jae Young Seong , Jong Ik Hwang , Eun Bee Cho , Junho Chung , Junyeong Jin , Tae Young Yune , Jee Youn Lee
IPC: C07K16/18 , C07K7/00 , A61K39/00 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US12072339B2
公开(公告)日：2024-08-27
申请号：US16753295
申请日：2018-10-02
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young Seong , Byung Joo Ham , Min-Hyeok Lee , Nui Ha
IPC: G01N33/68 , C07K16/24 , C12Q1/6883
CPC classification number: G01N33/6896 , C07K16/24 , C12Q1/6883 , C07K2317/622 , C12Q2600/158 , G01N2800/304
Abstract: The present disclosure relates to a method of diagnosing a mood disorder in a subject comprising measuring serum FAM19A5 concentration with an antagonist (e.g., an antibody or antigen-binding fragment thereof) that specifically binds to FAM19A5. The present disclosure also relates to a method of treating a mood disorder in a subject in need thereof comprising administering to the subject an FAM19A5 antagonist.
-
Patent Agency Ranking
公开(公告)号：US11739141B2
公开(公告)日：2023-08-29
申请号：US16807902
申请日：2020-03-03
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young Seong , Jong Ik Hwang , Woong Sun , Eun Bee Cho , Won-Ki Kim
IPC: C07K16/24 , C12Q1/6886 , C07K16/18 , G01N33/577 , G01N33/68 , A61K39/00 , C07K14/47 , A61K38/17 , A61K48/00 , C12N15/113
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , C07K14/4701 , C07K14/4702 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/6896 , A61K2039/505 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N2310/11 , C12N2310/141 , C12Q2600/156 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
公开(公告)号：US10385098B2
公开(公告)日：2019-08-20
申请号：US15771078
申请日：2016-11-30
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young Seong , Jong-Ik Hwang , Dong-Hoon Kim , Gi Hoon Son , Yoo-Na Lee , Seongsik Yun , Arfaxad Reyes-Alcaraz
IPC: C07K7/08 , A61K38/00 , A61K9/19 , A61K9/00 , A61P25/06 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
公开(公告)号：US09579398B2
公开(公告)日：2017-02-28
申请号：US14378505
申请日：2013-02-15
Applicant: Neuracle Science Co., Ltd.
Inventor： Jae Young Seong , Jong Ik Hwang , Woong Sun , Eun Bee Cho , Won-ki Kim
IPC: A61K39/395 , A61P25/00 , A61K48/00 , A61K38/17 , C07K16/18 , C12N15/113 , C07K14/47 , C07K16/24 , C12Q1/68 , A61K39/00
CPC classification number: C07K16/24 , A61K38/1709 , A61K48/00 , A61K2039/505 , C07K14/4701 , C07K14/4702 , C07K16/18 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N15/113 , C12N2310/11 , C12N2310/141 , C12Q1/6886 , C12Q2600/156 , G01N33/577 , G01N33/6896 , G01N2333/47
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
Abstract translation: 本发明涉及涉及调节胶质发生的FAM19A5的药物用途，更具体地说，涉及使用FAM19A5预防，诊断或治疗中枢神经系统损伤，退行性脑病或中枢神经系统疾病，FAM19A5为 在脊椎动物的神经干细胞中扩散并调节胶质细胞发生。
-
公开(公告)号：US12202889B2
公开(公告)日：2025-01-21
申请号：US17723149
申请日：2022-04-18
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Bongcheol Kim , Jae Young Seong , Jong Ik Hwang , Eun Bee Cho , Junho Chung , Junyeong Jin , Tae Young Yune , Jee Youn Lee
IPC: C07K16/18 , A61K39/00 , C07K7/00 , G01N33/563
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
-
公开(公告)号：US11248023B2
公开(公告)日：2022-02-15
申请号：US16511976
申请日：2019-07-15
Applicant: NEURACLE SCIENCE CO., LTD.
Inventor： Jae Young Seong , Jong-Ik Hwang , Dong-Hoon Kim , Gi Hoon Son , Yoo-Na Lee , Seongsik Yun , Arfaxad Reyes-Alcaraz
IPC: C07K7/08 , A61K38/00 , A61P25/28 , A61P25/30 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/06 , A61K9/00 , A61K9/19
Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
